Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)

Lupus
M-C AmigoL J Jara

Abstract

In antiphospholipid syndrome (APS), certain principal manifestations are associated with a worse prognosis and organ damage. The objective of this paper is to describe the development and initial content, criterion and construct validity of a disease-specific cumulative damage index in patients with thrombotic APS (DIAPS). Through expert panel agreement, 47 items were considered to reflect damage in APS. This preliminary version of the DIAPS was submitted to four local and international clinical and research experts in APS who ranked each item according to severity. A Delphi exercise resulted in a final 37 item instrument. In the second phase, a cross-sectional study was conducted applying the DIAPS in patients included in a multicenter electronic registry of patients with APS. Quality of life related to health status was evaluated with the EuroQol for construct validation. An α Cronbach and correlation with the EuroQol scale were calculated with SPSS 20.0 (p < 0.05). We evaluated the DIAPS in 156 patients, 77% female, with a mean age at diagnosis 34.7 ± 5.5 years. A total of 69% had primary APS. Common comorbidities included obesity, depression and dyslipidemia. The most frequent manifestations resulting in sequelae were deep ...Continue Reading

References

Aug 5, 2000·QJM : Monthly Journal of the Association of Physicians·M G TektonidouH M Moutsopoulos
Sep 2, 2000·Journal of Autoimmunity·D Alarcón-SegoviaA R Villa
Sep 6, 2001·Rheumatic Diseases Clinics of North America·M C Amigo
Apr 16, 2002·Arthritis and Rheumatism·Ricard CerveraUNKNOWN Euro-Phospholipid Project Group
Jan 17, 2012·The Journal of Rheumatology·Eleftheria P GrikaPanayiotis G Vlachoyiannopoulos
Jan 3, 2013·The Journal of Rheumatology·Medha Barbhaiya, Doruk Erkan
Feb 13, 2013·The Journal of Rheumatology·Panayiotis G Vlachoyiannopoulos

❮ Previous
Next ❯

Citations

Jan 16, 2016·Current Rheumatology Reports·P AlbaM C Amigo
Mar 7, 2017·International Journal of Rheumatic Diseases·Gabriela Hernández-MolinaAntonio R Cabral
Oct 5, 2018·Annals of the Rheumatic Diseases·Imad UthmanMunther Khamashta
Aug 5, 2017·Nature Reviews. Rheumatology·Savino SciasciaMunther Khamashta
May 15, 2020·Current Rheumatology Reports·Marie DesnoyersStéphane Zuily
May 2, 2021·Current Rheumatology Reports·Doruk ErkanUNKNOWN APS ACTION Executive Committee
Jun 11, 2021·Advances in Rheumatology·Fatema T ElgengehyTamer A Gheita

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

EuroQol

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.